Instadose Pharma Corp. (INSD) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
5500 NORTH SERVICE ROAD, SUITE 301 BURLINGTON, ON L7L 6W6 |
| State of Incorp. | NV |
| Fiscal Year End | May 31 |
| Industry (SIC) | 251 - Household Furniture (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 2/28/2022 MRQ | 11/30/2021 | 11/30/2020 | 11/30/2019 | 11/30/2018 | 11/30/2017 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 0 | 0 | 1 | |||||
| Cash and cash equivalents | 0 | 0 | 1 | |||||
| Total current assets: | 0 | 0 | 1 | |||||
| Noncurrent Assets | ||||||||
| TOTAL ASSETS: | 0 | 0 | 1 | |||||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 9 | 0 | 1 | 1 | 1 | |||
| Accounts payable | 9 | 0 | 1 | 1 | 1 | |||
| Due to related parties | 82 | 56 | 33 | 12 | ||||
| Other undisclosed current liabilities | 154 | |||||||
| Total current liabilities: | 162 | 82 | 57 | 34 | 13 | |||
| Noncurrent Liabilities | ||||||||
| Total liabilities: | 162 | 82 | 57 | 34 | 13 | |||
| Equity | ||||||||
| Equity, attributable to parent | (162) | (82) | (57) | (33) | (12) | |||
| Common stock | 8 | 75 | 75 | 75 | 75 | |||
| Additional paid in capital | 402 | (51) | (51) | (51) | (51) | |||
| Accumulated deficit | (568) | (106) | (81) | (57) | (34) | |||
| Stockholders' equity note, subscriptions receivable | (3) | (2) | ||||||
| Total equity: | (162) | (82) | (57) | (33) | (12) | |||
| TOTAL LIABILITIES AND EQUITY: | 0 | 0 | 1 | |||||
Income Statement (P&L) ($ in thousands)
| 2/28/2022 TTM | 11/30/2021 | 11/30/2020 | 11/30/2019 | 11/30/2018 | 11/30/2017 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 3 | ||||||
| Cost of revenue | (1) | ||||||
| Gross profit: | 1 | ||||||
| Operating expenses | (762) | (8) | 24 | (25) | (32) | ||
| Other undisclosed operating loss | (18) | ||||||
| Operating income (loss): | (762) | (26) | 24 | (24) | (32) | ||
| Income (loss) from continuing operations before income taxes: | (762) | (26) | 24 | (24) | (32) | ||
| Income tax benefit | 119 | ||||||
| Income (loss) from continuing operations: | (643) | (26) | 24 | (24) | (32) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | (643) | (26) | 24 | (24) | (32) | |
| Net income (loss): | (643) | (26) | 24 | (24) | (32) | ||
| Other undisclosed net income (loss) attributable to parent | 181 | (47) | |||||
| Net loss available to common stockholders, diluted: | (462) | (26) | (23) | (24) | (32) | ||
Comprehensive Income ($ in thousands)
| 2/28/2022 TTM | 11/30/2021 | 11/30/2020 | 11/30/2019 | 11/30/2018 | 11/30/2017 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (643) | (26) | 24 | (24) | (32) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (643) | (26) | 24 | (24) | (32) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.